EVENITY® (ROMOSOZUMAB-AQQG) PRESCRIBER ORDER FORM						
Patient Name:			Date of Birth:			
Address:						
Phone:		Height: ☐ Inches ☐		☐ Inches ☐ cn	n Weight:	□ lbs □ kg
Clinical Information						
Primary Diagnosis Description:			ICD-10 Code:			
EVENIT	Y® (romosoz	umab-aqqg)	Prescri	iption		
☐ EVENITY® (Romosozumab-aqqg) 210mg injected subcutaneously in the upper arm, upper thigh, or abdomen by a healthcare professional once every month. Refill x 1 year.						
A full dose of EVENITY requires two single-use prefilled syringes						
Ancillary Orders						
Anaphylaxis Kit If this is a 1st dose, would you like Option Care Health to provide an anaphylaxis kit with the 1st dose? Yes						
I certify that the use of the indicated treatment is medically necessary, and I will be supervising the patient's treatment.						
Prescriber Signature: Date: Prescriber Information						
Prescriber Name:		Phone:			Fax:	
Address:		NPI:				
City, State:	Zip:	Offic	Office Contact:			
Fax completed form, insurance information, and clinical documentation to:						
CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that do not require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws. IMPORTANT WARNING: This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.						

V1.0 – 26 November 2024